title: [Pelvic lymphadenectomy and radical prostatectomy. Recommendations of the German S3 guideline].
abstract: Radical prostatectomy is the most frequently used treatment for localized prostate cancer. In contrast to other strategies radical prostatectomy has been shown to be superior to watchful waiting in a prospective randomized trial. According to the German S3 guideline patients have to be informed about the results of this trial prior to treatment decision. The aims and quality indicators of radical prostatectomy include--as has also been defined by the German Cancer Society for certified prostate cancer centers--complete removal of the prostate with negative surgical margins (R0) and preservation of continence as well as potency. In low-risk disease (according to D'Amico criteria) pelvic lymph node dissection may be abandoned. If lymphadenectomy is performed a minimum number of ten nodes should be obtained. An extended lymphadenectomy is recommended in locally advanced disease.Radical prostatectomy is a valid treatment option in locally advanced prostate cancer. In cases with Gleason score > or = 8 or clinical stage cT3/4 magnetic resonance imaging of the pelvis should be performed prior to treatment decision making. In patients undergoing radical prostatectomy (neo) adjuvant treatment should not be used (exception: adjuvant treatment for lymph node metastases). For the first time the German S3 guideline determines minimum surgery volumes aimed at quality assurance. Radical prostatectomy has to be performed under the supervision of an experienced surgeon. This includes the number of 50 prostatectomies per year and institution, 25 prostatectomies per surgeon, and an appropriate training program.
authors.affiliation: Klinik und Poliklinik für Urologie, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Fetscherstrasse 74, 01307 Dresden. marc-oliver.grimm@uniklinikum-dresden.de
authors.forename: M-O
authors.initials: MO
authors.lastname: Grimm
authors.forename: C
authors.initials: C
authors.lastname: Thomas
authors.forename: M
authors.initials: M
authors.lastname: Fröhner
authors.forename: T
authors.initials: T
authors.lastname: Wiegel
authors.forename: A
authors.initials: A
authors.lastname: Heidenreich
authors.forename: J W
authors.initials: JW
authors.lastname: Thüroff
authors.forename: M
authors.initials: M
authors.lastname: Wirth
mesh_terms: D019317:Evidence-Based Medicine; D005858:Germany; D006801:Humans; D008197:Lymph Node Excision; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis / Q000473:pathology; D008279:Magnetic Resonance Imaging; D008297:Male; D017410:Practice Guidelines as Topic; D011379:Prognosis; D011446:Prospective Studies; D011467:Prostate / Q000473:pathology; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000473:pathology / Q000601:surgery*; D011785:Quality Assurance, Health Care; D016032:Randomized Controlled Trials as Topic